Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Radiotherapy induces responses of lung cancer to CTLA-4 blockade.

Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, Heguy A, Imai N, Gnjatic S, Emerson RO, Zhou XK, Zhang T, Chachoua A, Demaria S.

Nat Med. 2018 Dec;24(12):1845-1851. doi: 10.1038/s41591-018-0232-2. Epub 2018 Nov 5.

2.

Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity.

Ito Y, Ashenberg O, Pyrdol J, Luoma AM, Rozenblatt-Rosen O, Hofree M, Christian E, Ferrari de Andrade L, Tay RE, Teyton L, Regev A, Dougan SK, Wucherpfennig KW.

J Exp Med. 2018 Oct 1;215(10):2617-2635. doi: 10.1084/jem.20180300. Epub 2018 Sep 5.

3.

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.

Ferrari de Andrade L, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF Jr, Harvey CJ, Kobold S, Pyrdol JW, Yoon C, Yuan GC, Hodi FS, Dranoff G, Wucherpfennig KW.

Science. 2018 Mar 30;359(6383):1537-1542. doi: 10.1126/science.aao0505.

4.

A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P, Long HW, Yuan GC, Doench J, Brown M, Liu XS, Wucherpfennig KW.

Science. 2018 Feb 16;359(6377):770-775. doi: 10.1126/science.aao1710. Epub 2018 Jan 4.

5.

Inhalation therapy with M1 inhibits experimental melanoma development and metastases in mice.

Ferrari de Andrade L, Mozeleski B, Leck AR, Rossi G, da Costa CR, de Souza Fonseca GuimarĂ£es F, Zotz R, Fialho do Nascimento K, Camargo de Oliveira C, de Freitas Buchi D, da Silva Trindade E.

Homeopathy. 2016 Feb;105(1):109-18. doi: 10.1016/j.homp.2015.08.007. Epub 2015 Sep 26.

PMID:
26828006
6.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L.

J Clin Invest. 2015 Jul 1;125(7):2904. doi: 10.1172/JCI82646. Epub 2015 Jun 15. No abstract available.

7.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L.

J Clin Invest. 2015 May;125(5):2077-89. doi: 10.1172/JCI77181. Epub 2015 Apr 20. Erratum in: J Clin Invest. 2015 Jul 1;125(7):2904. Chesi, Martha [corrected to Chesi, Marta].

8.

DNAM-1 expression marks an alternative program of NK cell maturation.

Martinet L, Ferrari De Andrade L, Guillerey C, Lee JS, Liu J, Souza-Fonseca-Guimaraes F, Hutchinson DS, Kolesnik TB, Nicholson SE, Huntington ND, Smyth MJ.

Cell Rep. 2015 Apr 7;11(1):85-97. doi: 10.1016/j.celrep.2015.03.006. Epub 2015 Mar 26.

9.

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.

Ferrari de Andrade L, Ngiow SF, Stannard K, Rusakiewicz S, Kalimutho M, Khanna KK, Tey SK, Takeda K, Zitvogel L, Martinet L, Smyth MJ.

Cancer Res. 2014 Dec 15;74(24):7298-308. doi: 10.1158/0008-5472.CAN-14-1339. Epub 2014 Oct 28.

Supplemental Content

Loading ...
Support Center